Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

VERAPAMIL HCL

All products: general benefit

Mylan-Verapamil SR · DIN 02450496 · 240mg · LA tablet

General benefitDormant since 2024-03-11 · checked 2026-09-19 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mylan-Verapamil SR · DIN 02450496 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2016-10-27 Daily cost (source): $1.7143 Health Canada: Dormant since 2024-03-11 · brand MYLAN-VERAPAMIL SR · ATC C08DA01 VERAPAMIL · form Tablet (extended-release) · route Oral · ingredients VERAPAMIL HYDROCHLORIDE 240 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Verapamil SR: Formulary list price $1.7143/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.7143 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93663 · Verify on the e-Formulary ↗ (DIN 02450496)

Source record
DIN 02450496: Mylan-Verapamil SR Raw flags: chronicUseMed=Y, sec3=Y Item: 240800128; group id 359; item number 0839; lccId None; manufacturer id MYL Source form: LA Tab; strength: 240mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.7143; ministry $1.7143 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02450496 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93663
Interchangeable products
Isoptin SR · DIN 00742554 · $1.7143
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Dormant since 2024-03-11 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN 24:08 Hypotensive Drugs (For Diuretics See 40:28)

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

CILAZAPRIL & HYDROCHLOROTHIAZIDE

· 2 products · General benefit · strengths: 5mg/12.5mg · Tab

CLONIDINE HCL

· 17 products · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) · strengths: 0.025mg, 0.1mg, 0.2mg · Tab

DOXAZOSIN MESYLATE

· 12 products · Listed, not a benefit (3), General benefit (9) · strengths: 1mg, 2mg, 4mg · Tab

ENALAPRIL MALEATE

· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

FELODIPINE

· 12 products · General benefit (10), Listed, not a benefit (2) · strengths: 2.5mg, 5mg, 10mg · ER Tab, SR Tab

FOSINOPRIL SODIUM

· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 35 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: angina resulting from coronary artery spasm
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. NIFEDIPINE · General benefit (5), Listed, not a benefit (3) 1 INDICATIONS NIFEDIPINE (nifedipine capsules) is indicated for: • Management of angina resulting from coronary artery spasm. PM: https://pdf.hres.ca/dpd_pm/00073685.PDF; date JUN 16, 2010; DIN 00725110; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS AA-VERAP (verapamil hydrochloride tablets) is indicated for: • Chronic stable angina of effort. • Angina resulting from coronary artery spasm. • Obstructive hypertrophic cardiomyopathy, where surgery is not otherwise indicated. • Atrial fibrillation or flutter with rapid ventricular response not otherwise controllable with digitalis preparations. • Follow-up treatment to the use of injectable verapamil hydrochloride in paroxysmal supraventricular tachycardia. • Treatment of mild to moderate essential hypertension. Concomitant use of verapamil hydrochloride with a diuretic or an angiotensin converting enzyme inhibitor has been shown to be compatible and to have additive blood pressure lowering effects. 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. Caution should be exercised when verapamil hydrochloride is admi… https://pdf.hres.ca/dpd_pm/00082059.PDF PM date: JUN 30, 1989 Source product: AA-VERAP; DIN 00782483; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)